Clinical Trial Results:
A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared to placebo and evaluating the effects of degarelix 2.5 mg started in the mid-luteal or early follicular phase on endometrial receptivity compared to a fixed gonadotrophin releasing hormone antagonist protocol in oocyte donors undergoing controlled ovarian hyperstimulation for assisted reproductive technologies
Summary
|
|
EudraCT number |
2006-004684-58 |
Trial protocol |
BE CZ ES |
Global completion date |
27 Aug 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Feb 2016
|
First version publication date |
14 May 2015
|
Other versions |
|
Summary report(s) |
FE 200486 CS24 summary report |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.